In the last trading session, 1.18 million Immunome Inc (NASDAQ:IMNM) shares changed hands as the company’s beta touched 1.93. With the company’s per share price at $8.47 changed hands at -$0.83 or -8.98% during last session, the market valuation stood at $736.56M. IMNM’s last price was a discount, traded about -98.47% off its 52-week high of $16.81. The share price had its 52-week low at $5.15, which suggests the last value was 39.2% up since then. When we look at Immunome Inc’s average trading volume, we note the 10-day average is 1.24 million shares, with the 3-month average coming to 1.14 million.
Analysts gave the Immunome Inc (IMNM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMNM as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Immunome Inc (NASDAQ:IMNM) trade information
Instantly IMNM was in red as seen at the end of in last trading. With action -5.10%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -29.28%, with the 5-day performance at -5.10% in the red. However, in the 30-day time frame, Immunome Inc (NASDAQ:IMNM) is -3.37% down. Looking at the short shares, we see there were 12.52 million shares sold at short interest cover period of 13.74 days.
The consensus price target for the stock as assigned by Wall Street analysts is 33, meaning bulls need an upside of 74.33% from its current market value. According to analyst projections, IMNM’s forecast low is 23 with 35 as the target high. To hit the forecast high, the stock’s price needs a -313.22% plunge from its current level, while the stock would need to soar -171.55% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -38.15%. The 2025 estimates are for Immunome Inc earnings to increase by 56.81%, but the outlook for the next 5-year period is at 24.72% per year.
IMNM Dividends
Immunome Inc is expected to release its next quarterly earnings report on 2025-May-12.
Immunome Inc (NASDAQ:IMNM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.48% of Immunome Inc shares while 83.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 94.07%. There are 83.28% institutions holding the Immunome Inc stock share, with REDMILE GROUP, LLC the top institutional holder. As of 2024-06-30, the company held 8.1579% of the shares, roughly 4.89 million IMNM shares worth $59.16 million.
FMR LLC holds the second largest percentage of outstanding shares, with 7.0257% or 4.21 million shares worth $50.95 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and T. Rowe Price Small-Cap Stock Fund, Inc. . With 3.08 shares estimated at $26.04 million under it, the former controlled 3.54% of total outstanding shares. On the other hand, T. Rowe Price Small-Cap Stock Fund, Inc. held about 3.28% of the shares, roughly 2.85 shares worth around $24.14 million.
